NEW ORLEANS– Henley Ion, a New Orleans-based life sciences technology company developing next generation innovations in medical devices, reports positive testing results of their protective device designed to provide respiratory protection, without the use of conventional filtration which can make breathing difficult.
In initial testing with Henley’s first prototype at a high-containment laboratory located at the Tulane National Primate Research Center, the Henley Ion Virus Defender removed >99% of SARS-CoV-2 bioaerosols under rigorous Biosafety Level 3 testing conditions.
Leading the team at Henley is Dr. Julian Henley, co-founder of the company behind the patent-pending technology that uses micronized electrostatic precipitation (mEP) to remove infectious bioaerosols from the air. The respirator device uses mEP directly integrated into the mask to effectively remove infectious aerosol particles from both inhaled and exhaled air – as opposed to filtration, which can be difficult to breathe through and wear over long periods of time.
“As a physician, we are field soldiers at war with disease. My top priorities are to help sick patients recover and prevent healthy people from falling ill, especially if the enemy is an airborne contagious virus,” said Henley. “The objective of our efforts at Henley Ion is to provide people with the means to protect themselves from airborne pathogens.”
Dr. Henley has been issued 34 patents over the course of his surgical and biotechnology career, and he has partnered with global industrial leaders including Dow Corning in manufacturing advanced medical technologies, including the artificial voice box. Dr. Henley is a Harvard and UCSF-trained physician and board-certified specialty surgeon and served as a clinical faculty member at Yale School of Medicine for over 22 years.
